{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:31:05Z","timestamp":1792089065130,"version":"4.4.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>The natural history of occult hepatitis B virus infection (OBI) and the mechanism involved in HBV reactivation are only partially understood. As regards people living with HIV (PLWH), HBV reactivation is estimated to occur with an incidence ratio of 0.019 cases per 100 person-year. Here we report the case of OBI reactivation in a HIV\/HCV co-infected patient followed for 25 years at our Infectious Diseases Unit, but, unfortunately, lost to follow-up about 19 months after Direct-acting antivirals (DAAs) treatment. At re-engagement, blood tests showed high replication of plasmatic HIV-RNA along with severe immunosuppression and normal levels of liver enzymes. However, 3 months after ART reintroduction, an immune reconstitution inflammatory syndrome (IRIS) was diagnosed with high detectable HBV-DNA load and transaminase elevation. Our case report shows how the balance between the virus and the host immune system is quite a dynamic process that might significantly impact the course of the disease. The aim of this case report is to bring to the attention of physicians that, although OBI reactivation is a rather rare occurrence, even amongst PLWH, its potential consequences compel to a high alertness on the matter. Therefore, especially in patients with an impaired immune system and on a tenofovir or lamivudine-sparing regimen, HBV serological and virological markers should always be strictly monitored, even in the absence of a hepatitis flare.<\/jats:p>","DOI":"10.3389\/fcimb.2023.1143346","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:29:17Z","timestamp":1681446557000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Case report: An occult hepatitis B virus infection reactivation in an HIV\/HCV coinfected patient during an immune reconstitution inflammatory syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Serena","family":"Zaltron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cambianica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Di Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Colangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Storti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Tiecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Quiros-Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"B1","unstructured":"BrustJ. C. M.\n            McGowanJ. P.\n            FineS. M.\n            MerrickS. T.\n            RadixA. E.\n            VailR. M.\n          Management of immune reconstitution inflammatory syndrome (IRIS)2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3390\/cells10051114","article-title":"CD4+ T cells in chronic hepatitis b and T cell-directed immunotherapy","volume":"10","author":"Buschow","year":"2021","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11904-018-0379-y","article-title":"Significance and management of isolated hepatitis b core antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA era","volume":"15","author":"Chang","year":"2018","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"B4","unstructured":"EACS guidelines version 11.02021"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.12998\/wjcc.v10.i17.5518","article-title":"Occult hepatitis b \u2014 the result of the host immune response interaction with different genomic expressions of the virus","volume":"10","author":"Gherlan","year":"2022","journal-title":"World J. Clin. cases"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02240","article-title":"Heterogeneity of HBV-specific CD8+ T-cell failure: Implications for immunotherapy","volume":"10","author":"Heim","year":"2019","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/2325957415586258","article-title":"Outcomes in HIV\/HBV-coinfected patients in the tenofovir era are greatly affected by immune suppression","volume":"14","author":"Huang","year":"2015","journal-title":"J. Int. Assoc. Provid. AIDS Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac451","article-title":"Hepatitis b\u2013related hepatic flare during immune reconstitution syndrome after antiretroviral treatment initiation in an HBV surface antigen\u2013positive patient with HIV: Viroimmunological and histological characterization","volume":"9","author":"Iannetta","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S2468-1253(22)00201-1","article-title":"Prevalence of occult hepatitis b virus infection in adults: a systematic review and meta-analysis","volume":"7","author":"Im","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B10","unstructured":"Epidemiology - SEIEVA data. EpiCentro - epidemiology for public health2022"},{"key":"B11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.7861\/clinmedicine.18-3-212","article-title":"Hepatitis b virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians","volume":"18","author":"Koffas","year":"2018","journal-title":"Clin. Med. (Northfield Il)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis b virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5009\/gnl210551","article-title":"Risk of hepatitis b virus (HBV) reactivation in HBsAg-negative, anti-HBc-Negative patients receiving rituximab for autoimmune diseases in HBV endemic areas","volume":"7","author":"Lan","year":"2023","journal-title":"Gut Liver"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1097\/QAD.0000000000002941","article-title":"Hepatitis b reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis b virus infection and poor immunological status","volume":"35","author":"Mican","year":"2021","journal-title":"AIDS"},{"key":"B15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis b virus reactivation during direct-acting antiviral therapy for hepatitis c: a systematic review and meta-analysis","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis b virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological association institute technical review on prevention and treatment of hepatitis b virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.bjid.2015.11.007","article-title":"Prevalence and characteristics of HIV\/HBV and HIV\/HCV coinfections in Tuscany","volume":"20","author":"Puglia","year":"2016","journal-title":"Braz. J. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Update of the statements on biology and clinical impact of occult hepatitis b virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/QAD.0b013e3280ad47f5","article-title":"Hepatitis b reverse seroconversion in HIV-positive patients: Case series and review of the literature","volume":"21","author":"Rouphael","year":"2007","journal-title":"AIDS"},{"key":"B21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis b, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"7","author":"Sheena","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5754","DOI":"10.12998\/wjcc.v9.i21.5769","article-title":"Prevention of hepatitis b reactivation in patients requiring chemotherapy and immunosuppressive therapy","volume":"9","author":"Shih","year":"2021","journal-title":"World J. Clin. cases"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.1128\/jvi.67.10.5823-5832.1993","article-title":"Suppression of hepatitis b virus expression and replication by hepatitis c virus core protein in HuH-7 cells","volume":"67","author":"Shih","year":"1993","journal-title":"J. Virol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/MEG.0000000000001417","article-title":"Occult hepatitis b and HIV infection","volume":"31","author":"Soriano","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis b virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J. Virol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20614","article-title":"Acute phase HBV-specific T cell responses associated with HBV persistence after HBV\/HCV coinfection","volume":"22","author":"Urbani","year":"2005","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.775461","article-title":"The impact of HBV quasispecies features on immune status in HBsAg+\/HBsAb+ patients with HBV genotype c using next-generation sequencing","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/cid\/cis908","article-title":"Predictors of the isolated hepatitis b core antibody pattern in HIV-infected and-uninfected men in the multicenter AIDS cohort study","volume":"56","author":"Witt","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1073\/pnas.0913498107","article-title":"Immune effectors required for hepatitis b virus clearance","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/infdis\/jiaa662","article-title":"Impact of immune reconstitution-induced hepatic flare on hepatitis b surface antigen loss in hepatitis b Virus\/Human immunodeficiency virus-1 coinfected patients","volume":"223","author":"Yoshikawa","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.850665","article-title":"Hepatitis b virus-specific cellular immunity contributes to the outcome of occult hepatitis b virus infection","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Microbiol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74244-0","article-title":"Prevalence and viral loads of polyomaviruses BKPyV, JCPyV, MCPyV, TSPyV and NJPyV and hepatitis viruses HBV, HCV and HEV in HIV-infected patients in China","volume":"10","author":"Zhou","year":"2020","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1143346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:29:24Z","timestamp":1681446564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1143346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":32,"alternative-id":["10.3389\/fcimb.2023.1143346"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1143346","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1143346"}}